Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker NVCT
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 50,000 | $18.32 | $916.0K Buy | Form 4 ↗ |
| Jun 30, 2026 | Ron Bentsur Chairman & CEO, Director, 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 12,500 | $20.00 | $250.0K Buy | Form 4 ↗ |
| Nov 5, 2025 | Ron Bentsur Chairman & CEO, Director, 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 5,000 | $5.72 | $28.6K Buy | Form 4 ↗ |
| Nov 5, 2025 | Juan Sanchez Director | NVCT Nuvectis Pharma, Inc. | Buy | 13,000 | $5.79 | $75.3K Buy | Form 4 ↗ |
| Nov 5, 2025 | Matthew L. Kaplan Director | NVCT Nuvectis Pharma, Inc. | Buy | 11,000 | $5.84 | $64.2K Buy | Form 4 ↗ |
| Oct 27, 2025 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 72,836 | $6.28 | $457.4K Buy | Form 4 ↗ |
| Oct 24, 2025 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 35,034 | $6.15 | $215.5K Buy | Form 4 ↗ |
| Oct 23, 2025 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 46,900 | $6.06 | $284.2K Buy | Form 4 ↗ |
| Jun 20, 2025 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 5,603 | $7.99 | $44.8K Buy | Form 4 ↗ |
| Jun 18, 2025 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 28,043 | $8.05 | $225.7K Buy | Form 4 ↗ |
| Jun 17, 2025 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 5,399 | $8.11 | $43.8K Buy | Form 4 ↗ |
| May 12, 2025 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 21,167 | $8.11 | $171.7K Buy | Form 4 ↗ |
| May 9, 2025 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 5,395 | $8.98 | $48.4K Buy | Form 4/A ↗ |
| May 9, 2025 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 9,817 | $8.90 | $87.4K Buy | Form 4/A ↗ |
| May 9, 2025 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 9,850 | $8.95 | $88.2K Buy | Form 4/A ↗ |
| May 8, 2025 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 2,400 | $8.97 | $21.5K Buy | Form 4/A ↗ |
| May 8, 2025 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 100 | $8.71 | $871 Buy | Form 4/A ↗ |
| May 8, 2025 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 100 | $8.99 | $899 Buy | Form 4/A ↗ |
| Feb 7, 2025 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 240,000 | $5.00 | $1.2M Buy | Form 4 ↗ |
| Dec 24, 2024 | Ron Bentsur Chairman & CEO, Director, 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 4,500 | $4.65 | $20.9K Buy | Form 4 ↗ |
| Dec 13, 2024 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 17,000 | $4.70 | $79.9K Buy | Form 4/A ↗ |
| Dec 13, 2024 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 17,000 | $4.70 | $79.9K Buy | Form 4 ↗ |
| Dec 12, 2024 | Marlio Charles Mosseri 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 32,121 | $4.64 | $149.0K Buy | Form 4/A ↗ |
| Nov 19, 2024 | Enrique Poradosu Chief Science & Business Off | NVCT Nuvectis Pharma, Inc. | Buy | 2,000 | $4.99 | $9,980 Buy | Form 4 ↗ |
| Nov 15, 2024 | Ron Bentsur Chairman & CEO, Director, 10% owner | NVCT Nuvectis Pharma, Inc. | Buy | 20,000 | $4.92 | $98.4K Buy | Form 4 ↗ |
| Nov 7, 2024 | Michael J. Carson Vice President, Finance | NVCT Nuvectis Pharma, Inc. | Sale | 2,755 | $8.16 | $22.5K Sale | Form 4 ↗ |
26 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:28 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances